What is Agenus?
Agenus is dedicated to the research, development, and manufacturing of innovative immuno-oncology products, including checkpoint antibodies, cell therapies, and vaccines. Leveraging its proprietary Retrocyte Display discovery engine, the company generates fully human therapeutic antibody drug candidates. Headquartered in Lexington, Massachusetts, Agenus operates at the forefront of cancer immunotherapy, aiming to harness the body's own immune system to combat the disease. The company's comprehensive approach spans multiple therapeutic modalities, positioning it as a key player in the biopharmaceutical sector.
How much funding has Agenus raised?
Agenus has raised a total of $462.1M across 8 funding rounds:
Share Placement
$10M
Debt
$5M
Debt
$21.1M
Debt
$100M
Share Placement
$60M
Debt
$230M
Debt
$1M
Private Equity
$35M
Share Placement (2009): $10M with participation from Iroquois Capital, Hudson Capital Group, and Downsview Capital
Debt (2013): $5M, investors not publicly disclosed
Debt (2015): $21.1M, investors not publicly disclosed
Debt (2015): $100M, investors not publicly disclosed
Share Placement (2017): $60M backed by Incyte
Debt (2018): $230M with participation from HealthCare Royalty Partners
Debt (2020): $1M led by PPP
Private Equity (2020): $35M supported by Betta Pharmaceuticals Co., Ltd.
Key Investors in Agenus
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd. is a pharmaceutical company that has participated in Agenus's funding rounds. Further details on their specific investment focus or specialization are not provided in the available data.
HealthCare Royalty Partners
HealthCare Royalty Partners (HCRP) is a global healthcare investment firm focused on investing primarily in commercial stage healthcare product assets. Based in Stamford, Connecticut, HCRP's involvement suggests a strategic interest in Agenus's product development and commercialization potential.
Iroquois Capital
Iroquois Capital Group is a financial services firm specializing in investment opportunities, offering services to individual and institutional investors seeking financial growth. Their participation indicates a strategic financial backing for Agenus's growth initiatives.
What's next for Agenus?
The recent major strategic investment in Agenus signals a critical juncture for the company, likely enabling accelerated clinical development, expansion of manufacturing capabilities, and further research into its novel immuno-oncology platforms. As Agenus continues to mature, this capital infusion is expected to fuel its journey towards commercialization and solidify its market position. The company's focus on proprietary technologies like Retrocyte Display suggests a strategy centered on innovation and differentiation in the highly dynamic field of cancer therapeutics.
See full Agenus company page
